Macrolides for better resolution of community-acquired pneumonia: A global meta-analysis of clinical outcomes with focus on microbial etiology
Document Type
Article
Department
Pulmonary and Critical Care; Medicine
Abstract
Objectives: This meta-analysis examined the impact of macrolides on resolution of CAP and interpretation of clinical benefit according to microbiology; emphasis is given to data under-reported countries (URCs).
Methods: This meta-analysis included 63 publications published between 1994 and 2022. Publications were analyzed for resolution of CAP (6,465 patients) and 30-day mortality (58,759 patients). A separate meta-analysis was done for the prevalence of respiratory pathogens in URCs.
Results: Mortality after 30 days was reduced by the addition of macrolides (OR 0.65, 95% CI 0.51-0.82). The odds ratio (OR) of CAP resolution when macrolides were added to the treatment regimen was 1.23 (95% confidence interval [CI] 1.00-1.52). The most prevalent pathogen was Streptococcus pneumoniae (12.68%; 95% CI 9.36-16.95%). Analysis of the epidemiology from the URCs included 12 publications. The most prevalent pathogens were S. pneumoniae (24.91%) and Klebsiella pneumoniae (12.90%).
Conclusions: The addition of macrolides to the treatment regimen led to relative 35% decrease of 30-day mortality and to 23% relative increase resolution of CAP.
Registration: PROSPERO; number CRD42022325280.
Publication (Name of Journal)
International Journal of Antimicrobial Agents
Recommended Citation
Kyprianou, M.,
Dakou, K.,
Aktar, A.,
Aouina, H.,
Behbehani, N.,
Dheda, K.,
Juvelekian, G.,
Khattab, A.,
Mahboub, B.,
Zubairi, A.
(2023). Macrolides for better resolution of community-acquired pneumonia: A global meta-analysis of clinical outcomes with focus on microbial etiology. International Journal of Antimicrobial Agents.
Available at:
https://ecommons.aku.edu/pakistan_fhs_mc_med_pulm_critcare/186
Comments
Volume, issue, and pagination are not provided by the author/publisher.